Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs MorphoSys AG

Teva vs MorphoSys: A Decade of Cost Efficiency

__timestamp	MorphoSys AG	Teva Pharmaceutical Industries Limited
Wednesday, January 1, 2014	77000	9216000000
Thursday, January 1, 2015	77000	8296000000
Friday, January 1, 2016	97000	10044000000
Sunday, January 1, 2017	33000	11560000000
Monday, January 1, 2018	1796629	10558000000
Tuesday, January 1, 2019	12085198	9351000000
Wednesday, January 1, 2020	9174146	8933000000
Friday, January 1, 2021	32200000	8284000000
Saturday, January 1, 2022	48620000	7952000000
Sunday, January 1, 2023	58355000	8200000000
Monday, January 1, 2024		8480000000

Cracking the code

A Tale of Two Pharmaceutical Giants: Cost Efficiency Over Time

In the ever-evolving pharmaceutical industry, cost efficiency is a critical metric for success. This analysis compares the cost of revenue efficiency between Teva Pharmaceutical Industries Limited and MorphoSys AG from 2014 to 2023. Teva, a global leader, consistently reported a cost of revenue exceeding $8 billion annually, peaking in 2017. In contrast, MorphoSys AG, a smaller biotech firm, showed a dramatic increase in cost efficiency, with costs rising from a modest $77,000 in 2014 to over $58 million by 2023. This represents a staggering growth of over 75,000% in less than a decade. While Teva's costs have shown a slight decline, MorphoSys's rapid expansion highlights its aggressive growth strategy. This comparison underscores the diverse strategies and challenges faced by pharmaceutical companies in managing their cost structures effectively.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025